Den Europæiske Union - svensk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multipelt myelom - antineoplastiska medel - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipin, valsartan, hydroklortiazid - hypertension - angiotensin ii-antagonister, vanligt, angiotensin ii-antagonister, kombinationer - behandling av essentiell hypertoni som substitutionsterapi hos vuxna patienter vars blodtryck är adekvat kontrollerad på kombinationen av amlodipin, valsartan och hydroklortiazid (hct), tas antingen som tre single-komponent formuleringar eller som en dual-komponent och en single-komponent formulering.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

neovii biotech gmbh - catumaxomab - ascites; cancer - andra antineoplastiska medel - removab är indicerat för intraperitoneal behandling av maligna ascites hos patienter med epcam-positiva karcinomer där standardbehandling inte är tillgänglig eller inte längre möjlig.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcell - antineoplastiska medel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Den Europæiske Union - svensk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiska medel - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertension - kardiovaskulära systemet - behandling av essentiell hypertoni hos vuxna:lägg på therapyonduarp är indicerat hos vuxna vars blodtryck inte är adekvat kontrollerat om amlodipin. ersättning therapyadult patienter som fick telmisartan och amlodipin från separata tabletter kan i stället få tabletter av onduarp innehåller samma komponent doser.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

sanofi b.v. - agalsidas beta - fabry disease - andra matsmältningsorgan och ämnesomsättning produkter, - fabrazyme är indicerat för långvarig enzymbytebehandling hos patienter med en bekräftad diagnos av fabrys sjukdom (a-galaktosidas-a-brist).

Den Europæiske Union - svensk - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamid - epilepsi - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).